The U.S. Food and Drug Administration (FDA) has approved FoundationOne Liquid CDx to be used as a companion diagnostic test to identify men with metastatic castration-resistant prostate cancer (mCRPC) who are likely to benefit from treatment with Lynparza (olaparib). Developed by Foundation Medicine, the test is a blood-based biopsy assessment approved by the FDA to analyze the genetic signature of solid tumors, with the goal of identifying patients who may benefit from certain FDA-approved targeted…
You must be logged in to read/download the full post.
The post FDA Approves FoundationOne Liquid CDx as Companion Test for Lynparza in mCRPC Patients appeared first on BioNewsFeeds.